Evidence map›Paper›PMID 23956438›Full record

ArticleThe Journal of infectious diseases2014

Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus.

Peter V Aka, Mark H Kuniholm, Ruth M Pfeiffer, Alan S Wang, Wei Tang, Sabrina Chen, Jacquie Astemborski, Michael Plankey, Maria C Villacres, Marion G Peters and 8 more

Registry-linked trialAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00341484 (Genetic Susceptibility to Oncogenic Viruses), which is not on this map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00341484 completednot on this map

Genetic Susceptibility to Oncogenic Viruses

TypeobservationalSponsorNational Cancer Institute (NCI)Ran1998 to 2007Enrolled2,580ConditionsLiver Neoplasms, HIV Infections
3 · Its place in the literature

Who cites it

61 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Interferon lambda 4 is a gut antimicrobial protein.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  6. Review
  7. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2023
    Article
  8. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2023
    Article
  9. Polymorphisms of theFrontiers in cellular and infection microbiology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Innate Immunity in Hepatitis C Virus Infection.Cold Spring Harbor perspectives in medicine · 2021
    Review
  17. Article
  18. Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Peter V AkaInfections and Immunoepidemiology Branch.
Mark H Kuniholm
Ruth M Pfeiffer
Alan S Wang
Wei Tang
Sabrina Chen
Jacquie Astemborski
Michael Plankey
Maria C Villacres
Marion G Peters
Seema Desai
Eric C Seaberg
Brian R Edlin
Howard D Strickler
David L Thomas
Ludmila Prokunina-Olsson
Gerald B Sharp
Thomas R O'Brien

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
INCIDENCE OF HIV INFECTIONS IN A COHORT OF IV DRUG USERSR01DA012568 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MEHTA, SHRUTI H · 1999 to 2017
$15.5M
NATURAL HISTORY OF HIV INFECTION IN INJECTION DRUG USERSR37DA004334 · NIDA · JOHNS HOPKINS UNIVERSITY · PI KIRK, GREGORY D · 1997 to 2006
$9.0M
Intramural NIH HHSNCATS NIH HHS UL1 TR001079NCI NIH HHS N01 CO012400NCI NIH HHS N01-CO-12400NCI NIH HHS N02-CP-91027NCRR NIH HHS UL1 RR024131NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01-AI-35004NIAID NIH HHS UO1-AI-31834NIAID NIH HHS UO1-AI-34989NIAID NIH HHS UO1-AI-34993NIAID NIH HHS UO1-AI-34994NIAID NIH HHS UO1-AI-42590NICHD NIH HHS U01 HD032632NICHD NIH HHS UO1-HD-32632NIDA NIH HHS DA033541NIDA NIH HHS DA04334NIDA NIH HHS DA12568NIDA NIH HHS R01 DA004334NIDA NIH HHS R01 DA009532NIDA NIH HHS R01 DA012109NIDA NIH HHS R01 DA012568NIDA NIH HHS R01 DA013245NIDA NIH HHS R01 DA016159NIDA NIH HHS R01 DA033541NIDA NIH HHS R01-DA09532NIDA NIH HHS R01-DA13245NIDA NIH HHS R01-DA16159NIDA NIH HHS R37 DA004334NIDA NIH HHS R56 DA004334NIDA NIH HHS R56 DA012568NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

Interferon lambda 4 protein can be generated in IFNL4-ΔG carriers but not IFNL4-TT homozygotes. We studied 890 anti-hepatitis C virus (HCV)-positive participants in the Women's Interagency HIV Study. Among blacks (n = 555), HCV was more often cleared for those with genotype IFNL4-TT/TT (32.6%; odds ratio [OR], 3.59; P = 3.3 × 10(-5)) than IFNL4-TT/ΔG (11.3%; OR, 0.95; P = .86) or IFNL4-ΔG/ΔG (11.9%; referent). Pooling these data with published results in blacks (n = 1678), ORs were 3.84 (P = 8.6 × 10(-14)) for IFNL4-TT/TT and 1.44 (P = .03) IFNL4-TT/ΔG, and the area under the curve was 0.64 for IFNL4-ΔG genotype and 0.61 for rs12979860 (IL28B). IFNL4-ΔG is strongly associated with impaired spontaneous HCV clearance.

Indexed as

Genetic Predisposition to DiseaseAdultAllelesBlack or African AmericanCohort StudiesFemaleHepacivirusHepatitis CHumansInterferon LambdaInterleukinsProspective StudiesIFNL4 protein, humanInterferon LambdaInterleukinsgeneticHCVIFNL4IL28Bviral clearance

Identifiers

PMID23956438
PMCPMC3883162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.